ARGHYA SETT

Dr. ARGHYA SETT

orcid
Research Scientist at Luxembourg Institute of Science and Te...

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Advances in Natural Sciences: Nanoscience and Nanotechnology
Verified
Journal Article
Open access
PDF file
ARGHYA SETTARGHYA SETT
ARGHYA SETT
MGManoj Gadewar
Manoj Gadewar
PSPragya Sharma
Pragya Sharma
MDManab Deka
Manab Deka
UBUtpal Bora
Utpal Bora
Green synthesis of gold nanoparticles using aqueous extract of Dillenia indica View the table of contents for this issue, or go to the journal homepage for more 2016 Adv. Nat. Sci: Nanosci. Nanotechnol. 7 025005

10 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFrancesco Millozzi
Francesco Millozzi
PMPaula Milán
Paula Milán
ARGHYA SETTARGHYA SETT
ARGHYA SETT
GCGiovanni Delli Carpini
Giovanni Delli Carpini
MBMarco De Bardi
Marco De Bardi
DGDaniela Palacios García
Daniela Palacios García
Inefficient targeting of muscle stem cells (MuSCs), also called satellite cells, represents a major bottleneck of current therapeutic strategies for muscular dystrophies, as it precludes the possibility of promoting compensatory regeneration. Here we describe a muscle-targeting delivery platform, based on gold nanoparticles, that enables the release of therapeutic oligonucleotides into MuSCs. We demonstrate that AuNPs conjugation to an aptamer against α7/β1 integrin dimers directs either local or systemic delivery of microRNA-206 to MuSCs, thereby promoting muscle regeneration and improving muscle functionality, in a mouse model of Duchenne Muscular Dystrophy. We show here that this platform is biocompatible, non-toxic, and non-immunogenic, and it can be easily adapted for the release of a wide range of therapeutic oligonucleotides into diseased muscles.

17 July 2017 in Advances in Natural Sciences: Nanoscience and Nanotechnology
Verified
Journal Article
Open access
PDF file
SOSunita Ojha
Sunita Ojha
ARGHYA SETTARGHYA SETT
ARGHYA SETT
UBUtpal Bora
Utpal Bora

21 February 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ARGHYA SETTARGHYA SETT
ARGHYA SETT
BBB. B. Borthakur
B. B. Borthakur
UBUtpal Bora
Utpal Bora

4 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Rajesh AhirwarRajesh Ahirwar
Rajesh Ahirwar
SVShamsudheen Karuthedath Vellarikkal
Shamsudheen Karuthedath Vellarikkal
ARGHYA SETTARGHYA SETT
ARGHYA SETT
SSSridhar Sivasubbu
Sridhar Sivasubbu
VSVinod Scaria
Vinod Scaria
PNPradip Nahar
Pradip Nahar
An increase in the expression of estrogen receptors (ER) and the expanded population of ER-positive cells are two common phenotypes of breast cancer. Detection of the aberrantly expressed ERα in breast cancer is carried out using ERα-antibodies and radiolabelled ligands to make decisions about cancer treatment and targeted therapy. Capitalizing on the beneficial advantages of aptamer over the conventional antibody or radiolabelled ligand, we have identified a DNA aptamer that selectively binds and facilitates the detection of ERα in human breast cancer tissue sections. The aptamer is identified using the high throughput sequencing assisted SELEX screening. Biophysical characterization confirms the binding and formation of a thermodynamically stable complex between the identified DNA aptamer (ERaptD4) and ERα (Ka = 1.55±0.298×108 M-1; ΔH = 4.32×104±801.1 cal/mol; ΔS = -108 cal/mol/deg). Interestingly, the specificity measurements suggest that the ERaptD4 internalizes into ERα-positive breast cancer cells in a target-selective manner and localizes specifically in the nuclear region. To harness these characteristics of ERaptD4 for detection of ERα expression in breast cancer samples, we performed the aptamer-assisted histochemical analysis of ERα in tissue samples from breast cancer patients. The results were validated by performing the immunohistochemistry on same samples with an ERα-antibody. We found that the two methods agree strongly in assay output (kappa value = 0.930, p-value <0.05 for strong ERα positive and the ERα negative samples; kappa value = 0.823, p-value <0.05 for the weak/moderate ER+ve samples, n = 20). Further, the aptamer stain the ERα-positive cells in breast tissues without cross-reacting to ERα-deficient fibroblasts, adipocytes, or the inflammatory cells. Our results demonstrate a significant consistency in the aptamer-assisted detection of ERα in strong ERα positive, moderate ERα positive and ERα negative breast cancer tissues. We anticipate that the ERaptD4 aptamer targeting ERα may potentially be used for an efficient grading of ERα expression in cancer tissues.

6 June 2014 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
ARGHYA SETTARGHYA SETT
ARGHYA SETT
SDSuradip Das
Suradip Das
UBUtpal Bora
Utpal Bora